戻る Agenda
EMA 2030 and beyond - How should the EMA of the Future look like - Stakeholder Expectations
Session Chair(s)
Sabine Atzor, MPharm, RPh
Head of EU Regulatory Policies
F. Hoffmann-La Roche Ltd, Switzerland
The Pharmaceutical Strategy will lead to non-legislative and legislative measures of the Pharma Acquis. To contribute to this discussion, the session is intended to collect bold visions of different stakeholders for "EMA 2030 and beyond".
Learning Objective : - understand the needs for EMA to evolve to enable future science & technology, including personalised medicines/ personalised healthcare - understand perspectives of different stakeholders: patients, pharma & medtech industry, HTA bodies, academia
Speaker(s)
Panelist
Tony Humphreys, MPharm
European Medicines Agency, Netherlands
Head of the Regulatory Science and Innovation Task Force
Panelist
Alan Morrison, PhD
MSD, United Kingdom
Vice President Regulatory Affairs Intl
Panelist
Jan Geissler, MBA
Patvocates, Germany
Managing Director
Panelist
Niklas Hedberg, MPharm
Dental and Pharmaceutical Benefits Agency, TLV, Sweden
HTACG Co-Chair & Chief Pharmacist
Panelist
Shayesteh Fürst-Ladani, MBA, MS
SFL Regulatory Affairs & Scientific Communication, Switzerland
CEO
Panelist
Ilona Reischl, PhD, MPharm
Austrian Medicines and Medical Devices Agency (AGES MEA), Austria
Biologics Quality Assessor